Understanding “Wearing-off” in patients receiving calcitonin gene-related peptide pathway monoclonal antibodies for the preventive treatment of migraine
Understanding “Wearing-off” in patients receiving calcitonin gene-related peptide pathway monoclonal antibodies for the preventive treatment of migraine is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Understanding “Wearing-off” in patients receiving calcitonin gene-related peptide pathway monoclonal antibodies for the preventive treatment of migraine have?
Understanding “Wearing-off” in patients receiving calcitonin gene-related peptide pathway monoclonal antibodies for the preventive treatment of migraine has 1 citations in the OpenAlex counts ScholarIQ stores.
When was Understanding “Wearing-off” in patients receiving calcitonin gene-related peptide pathway monoclonal antibodies for the preventive treatment of migraine published?
Understanding “Wearing-off” in patients receiving calcitonin gene-related peptide pathway monoclonal antibodies for the preventive treatment of migraine has 2023 year in the ScholarIQ index.
What is the open-access status of Understanding “Wearing-off” in patients receiving calcitonin gene-related peptide pathway monoclonal antibodies for the preventive treatment of migraine?
Understanding “Wearing-off” in patients receiving calcitonin gene-related peptide pathway monoclonal antibodies for the preventive treatment of migraine has bronze oa status in the ScholarIQ index.
What is the DOI of Understanding “Wearing-off” in patients receiving calcitonin gene-related peptide pathway monoclonal antibodies for the preventive treatment of migraine?
The DOI for Understanding “Wearing-off” in patients receiving calcitonin gene-related peptide pathway monoclonal antibodies for the preventive treatment of migraine is on the source record.
What is the OpenAlex record for Understanding “Wearing-off” in patients receiving calcitonin gene-related peptide pathway monoclonal antibodies for the preventive treatment of migraine?
The OpenAlex for Understanding “Wearing-off” in patients receiving calcitonin gene-related peptide pathway monoclonal antibodies for the preventive treatment of migraine is on the source record.